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ABSTRACT
Biliary excretion is an important route of elimination and the
biliary tract is a potential site of toxicity for many drugs and
xenobiotics. Quantification of biliary excretion in healthy
human volunteers is logistically challenging and is rarely
defined during drug development. The current study uses a
novel oroenteric tube coupled with a specialized clinical pro-
tocol to examine the pharmacokinetics of 99mTechnetium
(Tc-99m) mebrofenin, a compound that undergoes rapid
hepatic uptake and extensive biliary excretion. A custom-
made multilumen oroenteric tube was positioned in the duo-
denum of healthy human volunteers. Subjects were posi-
tioned under a gamma camera and 2.5 mCi of Tc-99m
mebrofenin was administered intravenously. Duodenal aspi-
rates, blood samples, and urine were collected periodically
for 3 hours. Two hours after Tc-99m mebrofenin administra-
tion, the gallbladder was contracted with an intravenous infu-
sion of cholecystokinin-8. Gamma scintigraphy was used to
determine the gallbladder ejection fraction in each subject.
Total systemic clearance of Tc-99m mebrofenin approximat-
ed liver blood flow (Cltotal 17.3 ± 1.7 mL/min/kg), and 35%
to 84% of the Tc-99m mebrofenin dose was recovered in
bile. However, when the data were corrected for the gallblad-
der ejection fraction, 71% to 92% of the excreted Tc-99m
mebrofenin dose was recovered. This novel oroenteric tube
and clinical protocol provide a useful method to quantify bil-
iary excretion of xenobiotics in healthy human volunteers.
KEYWORDS: oroenteric tube, gallbladder, Tc-99m mebro-
fenin, biliary excretion, biliary clearance.
INTRODUCTION
With the advent of combinatorial chemistry, an increasing
number of new chemical entities characterized by high molec-
ular weight and lipophilicity are being synthesized and
screened during the drug discovery process.1 Drugs with these
physicochemical characteristics often are associated with sig-
nificant hepatic metabolism and excretion via the biliary
route.2 Therefore, new tools and techniques are needed to
investigate and predict biliary excretion of investigational
drugs in healthy human volunteers. Currently, limited informa-
tion is available regarding the extent of biliary elimination of
drugs and metabolites, primarily because of the difficulty in
obtaining bile samples from healthy human subjects. Biliary
excretion data would be extremely valuable in evaluating the
contribution of biliary clearance to total systemic clearance,
elucidating potential mechanisms of hepatobiliary toxicity, and
examining enterohepatic recirculation. In addition, the Food
and Drug Administration (FDA) recently published guidelines
detailing the requirements for drug-drug interaction studies
necessary in New Drug Application submissions. These guide-
lines suggest that mechanisms of interactions should be
explored, rather than simply performing observational stud-
ies.3 Therefore, a method to investigate potential drug interac-
tions that occur during biliary elimination may increase the
quality of information provided to registration agencies and
help avoid the withdrawal of drugs from the market as a result
of a serious, but foreseeable, drug interaction.
One valuable preclinical tool to investigate biliary clearance
of drugs is the sandwich-cultured hepatocyte model. This
model has been developed using rat and human hepatocytes
to examine biliary excretion in vitro, and has been validated
with in vivo data collected from rats.4 However, the in vivo
data required to develop an in vitro–in vivo correlation of bil-
iary clearance for humans is lacking. This shortcoming is pri-
marily a result of the difficulty in obtaining biliary excretion
data in humans, particularly in healthy volunteers.
Historically, there has been little success in the development
of valid and reliable techniques to quantify biliary excretion
of drugs or endogenous compounds in humans. Such data
may be obtained from patients suffering from gallbladder dis-
ease requiring removal of the gallbladder. Typically, patients
are administered the drug of interest prior to surgery, and the
amount of drug found in the gallbladder after removal is
quantified.5,6 This approach only allows a single time point
determination of drug content in bile. More commonly, stud-
ies employ patients that require a temporary bile shunt (T-
tube) that diverts bile from the liver to a transcutaneous port
for external collection.7,8 With this method, biliary excretion
may be determined over time while the shunt is in place.
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The major limitation of both of the above techniques is the use
of patients with significant hepatobiliary disease as study sub-
jects. Several studies have employed healthy human volun-
teers and oroenteric tubes to withdraw pancreatic-biliary secre-
tions from the duodenum.9 These studies have used occlusive
balloons to facilitate more complete bile collection,10 or have
perfused nonabsorbable markers into the duodenum to evalu-
ate recovery.11,12 A significant advantage of these techniques is
the ability to conduct studies in healthy human volunteers, par-
ticularly in light of the role of hepatobiliary transport proteins
in hepatic drug disposition. Certain disease states may signifi-
cantly influence transport protein expression, function, local-
ization, and/or bile flow along the bile canaliculi, thereby alter-
ing drug secretion and excretion patterns.13-15
Previous studies conducted in healthy human volunteers
have resulted in incomplete and highly variable recovery of
compounds excreted in bile.10,16 This is primarily a result of
difficulties in obtaining and assessing the completeness of
bile collection, and a lack of control over gallbladder con-
traction. Described here is a method using a novel oroenteric
tube and specialized clinical protocol that facilitates efficient
recovery of biliary secretions and optimal gallbladder refill-
ing status and contractibility. The use of the gamma emitter
99mTechnetium (Tc-99m) mebrofenin as a probe compound
in this study allowed real-time assessment of biliary excre-
tion, gallbladder ejection fraction, and the efficiency of bile
collection. This compound is available for intravenous
administration, is not significantly metabolized, and is prin-
cipally excreted unchanged in bile.
MATERIALS AND METHODS
Catheter Design
A commercially available oroenteric catheter extrusion was
modified according to the design in Figure 1 to aspirate
secretions from the gastric and duodenal regions of the
human gastrointestinal tract (Dentsleeve, Wayville,
Australia). Briefly, the tube is a silicone multilumen extru-
sion 4.5 mm in diameter, 128 cm long, with 3 tungsten tip
weights to facilitate passage of the tube through the pyloric
sphincter. The distal/terminal end of the tube was fitted with
a welded polyethylene balloon to facilitate migration of the
tube during placement, and to ensure occlusion of the intes-
tine during the bile collection period. The balloon (9 cm long
× 4.7 cm wide, uninflated) was single use and fitted to metal
balloon attachment rings using 1.0 silk suture. Two of the
large lumens of the extrusion (Figure 1, Panel A, lumens A
and C) were dedicated to aspiration of secretions from the
duodenal region, while lumen E was used for aspiration from
the gastric region. Aspiration vacuum relief was provided by
lumens B, D, and F. Lumen G was used to inflate/deflate the
polyethylene balloon and lumen H provided a saline flush to
Figure 1. (A) Cross-sectional diagram of the oroenteric tube. Lumen labels correspond to the following functions: A, duodenal aspira-
tion 1; B, duodenal aspiration 1 vacuum relief; C, duodenal aspiration 2; D, duodenal aspiration 2 vacuum relief; E, gastric aspiration;
F, gastric aspiration vacuum relief; G, balloon inflation; H, saline flush. (B) Schematic of oroenteric tube. Syringe connector labels cor-
respond to the following channels: I, duodenal aspiration 1 and 2; II, gastric aspiration; III, duodenal aspiration 1 and 2 vacuum relief;
IV, gastric aspiration vacuum relief; V, balloon inflation/deflation; VI, saline flush.
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reduce viscosity of the duodenal secretions. A radio-opaque
pyloric marker was positioned 100 cm from the syringe con-
nectors to facilitate correct placement of the tube under fluo-
roscopy.
Clinical Protocol
Four nonsmoking volunteers (20-24 years of age; 3 male, 1
female) within 20% of ideal body weight (64.5-84.4 kg)
completed the study. All procedures were approved by the
Clinical Research Advisory Committee and the Committee
on the Protection of the Rights of Human Subjects of the
University of North Carolina (UNC) at Chapel Hill School of
Medicine. Subjects provided written informed consent prior
to participation in the study and were healthy as indicated by
their medical history, physical examination, routine laborato-
ry tests, and electrocardiogram. Subjects were asked to
abstain from any medication (with the exception of oral con-
traceptives) for 2 weeks prior to the study, and to abstain
from caffeine and alcohol during the study. Subjects were
admitted to the General Clinical Research Center of UNC
Hospitals the evening before the study and given a high-fat
meal (~55 g of fat) at 18:00 hours and a high-fat snack (~45
g of fat) at 23:00 hours. Subjects then remained fasted until
the end of the study. At 06:00 the following morning, the
oroenteric tube was passed through the mouth and positioned
with the aid of dynamic fluoroscopic radiography (ICONOS
R200, Seimens, Hoffman Estates, IL). Correct placement of
the tube was judged by the position of the pyloric marker
(right-hand margin of spine) and the tip weights (immediate-
ly distal to the Ligament of Treitz) (Figure 2). Subjects were
then positioned supine under a gamma camera (E-CAM Dual
Head Gamma Camera, Siemens); baseline blood, urine, and
bile samples were collected; and the occlusive polyethylene
balloon was inflated with ~20 mL of air until the subjects
experienced mild discomfort. Subjects were then adminis-
tered a 2.5 mCi IV bolus dose of Tc-99m mebrofenin (Squibb
Diagnostics, Princeton, NJ) via a forearm vein indwelling
catheter (specific activity 0.8-1.1 mCi/mg at time of prepara-
tion). Blood samples (3 mL) were collected at 1, 2.5, 5, 7.5,
10, 20, 40, 60, 80, 100, 120, 140, 165, and 180 minutes post-
dose from the contralateral arm. Biliary secretions collected
from the occluded duodenal region were continuously aspi-
rated and pooled over the following intervals: 0-5, 5-10, 10-
30, 30-50, 50-70, 70-90, 90-110, 110-120, 120-130, 130-150,
and 150-180 minutes postdose. Anterior gamma scintigraph-
ic images of the abdomen were acquired under dynamic
mode at 1-minute intervals and analyzed using ESOFT 2.5
software (Siemens). Two hours post-Tc-99m mebrofenin
administration, cholecystokinin-8 (sincalide, 0.02 µg/kg,
Bracco Diagnostics, Princeton, NJ) was administered as an
IV infusion over 30 minutes to facilitate contraction of the
gallbladder. Cholecystokinin-8 is an octa-peptide derived
from cholecystokinin and has a very short duration of action
(half-life in blood of 2.5 minutes).17,18 Urine was collected at
the conclusion of the sampling period (180 minutes).
Whole blood radioactivity was determined by gamma scintil-
lation counting (Quantum-8 Multichannel Analyzer, Oak
Ridge, TN). Bile collected over each interval and an aliquot
of urine were analyzed by a CRC-15R dose calibrator
(Capintec, Ramsay, NJ). All samples were corrected for
decay based on the Tc-99m half-life of 6.01 hours. Linearity
of the gamma camera response was assessed using 250-mL
saline bags injected with predetermined amounts of radioac-
tivity (0.5-3 mCi) measured with a CRC-15R dose calibrator.
Data Analysis
A duplicate dose of Tc-99m mebrofenin was prepared at the
same time as the dose administered to the subject and used
for calculation of the “theoretical dose.” This reference stan-
dard also was used to convert the units of the whole blood
radioactivity from counts per minute (cpm) to nCi, in order
to obtain a more quantitative measurement of the amount of
Figure 2. A representative fluoroscopic image of the oroenteric
tube correctly positioned. Arrows indicate the following: A, radio-
opaque marker at the pyloric sphincter; B, balloon attachment
rings; C, tungsten tip weights positioned at the Ligament of Treitz.
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radioactivity present in blood. After assessing the radioactiv-
ity remaining in the syringe, IV tubing, and catheter, the
“administered dose” was then calculated by difference.
Biliary recovery and urinary recovery were calculated as the
percentage of the administered dose that accumulated in bile
and urine, respectively, 180 minutes after dosing. A gallblad-
der ejection fraction (EF) was calculated from planar scinti-
graphic images using the following equation:
where GB represents the counts per minute in the gallbladder
region of the image pre- (time = 120 minutes) and post- (time
= 150 minutes) infusion of cholecystokinin-8.
In order to account for the variable contractile response of the
gallbladder, the total amount of radioactivity collected from
the duodenal region during the 30-minute infusion of chole-
cystokinin-8 was divided by the ejection fraction. This cor-
rection accounted for the Tc-99m mebrofenin remaining in
the gallbladder after contraction. Addition of this value to the
cumulative amount of Tc-99m mebrofenin collected in the
first 120 minutes of the study represented the total amount of
Tc-99m mebrofenin transported from the liver into bile, and
the amount that would have been collected if the gallbladder
were to contract completely.
where X0 represents the administered dose; XBile, the amount of
Tc-99m mebrofenin recovered in biliary secretions collected
over the time interval specified; and EF, the ejection fraction.
Therefore, estimates the total amount of Tc-99m
mebrofenin that would have been collected from the duodenal
region if the EF = 1. This corrected amount, expressed as a per-
centage of the administered dose, represents the recovery of Tc-
99m mebrofenin excreted from the gallbladder during the
study, and assumes that no additional Tc-99m mebrofenin
remains to be excreted into the duodenum from 150 to 180 min-
utes. Therefore this value can therefore provide an estimate of
recovery efficiency and performance of the oroenteric tube.
Pharmacokinetic Data Analysis
Blood activity-time profiles were analyzed by noncompart-
mental analysis using WinNonlin (Version 4.1, Pharsight
Corp, Mountain View, CA). The frequency of the blood sam-
pling at the beginning of the experiment and the slow clear-
ance of radioactivity from the injection site allowed the char-
acterization of Tc-99m mebrofenin distribution into the sys-
temic circulation. Therefore, the kinetics of administration
were modeled as an IV infusion of duration Tmax to account
for this observation. The area under the blood concentration-
time curve (AUC) was calculated using the linear trapezoidal
rule, and where appropriate, extrapolated to infinity using the
slope obtained from linear regression of the last 5 to 6 time
points. Total blood clearance of Tc-99m mebrofenin was
determined as the ratio of the administered dose and the AUC
extrapolated through infinite time. Biliary clearance was
determined as the ratio of the cumulative amount of Tc-99m
mebrofenin recovered in bile from 0 to 180 minutes (not cor-
rected for EF) and the AUC from 0 to 180 minutes.
RESULTS
Proper positioning of the oroenteric tube required between
0.5 and 2 hours. However, 1 subject failed to pass the tube
through the pylorus and into the duodenum in the allocated
time and, therefore, did not complete the study. Correct posi-
tioning of the oroenteric tube was confirmed by fluoroscop-
ic radiography. A representative image of the tube located in
the correct anatomical position is shown in Figure 2. The
marker at the pyloric sphincter and the tungsten tip weights
just beyond the Ligament of Treitz (immediately preceded by
the 2 balloon attachment rings) are clearly visible.
As expected, rapid and extensive biliary excretion of Tc-99m
mebrofenin was observed. As evident in animated Figure 3
(Panels A, B, C, and D), after IV administration Tc-99m
mebrofenin was rapidly taken up into the liver, secreted into
the canalicular space, and collected in the common bile duct
and gallbladder. Despite the consistency in the rate and
extent of Tc-99m mebrofenin accumulation in the gallblad-
der, each subject exhibited a different pattern of bile secre-
tion into the intestine, presumably due to differing sponta-
neous contraction patterns of the gallbladder.19 These differ-
ing release patterns of Tc-99m mebrofenin in bile are evident
in animated Figure 3 and in the profiles shown in Figure 4.
Subject 1 did not expel Tc-99m mebrofenin from the gall-
bladder until administration of cholecystokinin-8 at 120 min-
utes, whereas subjects 2 and 4 exhibited partial spontaneous
contraction of the gallbladder prior to cholecystokinin-8. Of
interest, subject 3 immediately ejected bile and Tc-99m
mebrofenin into the intestine before accumulation in the gall-
bladder and did not respond to cholecystokinin-8 as quickly
or to the same extent as the other subjects.
The gamma camera images obtained during the study allow a
visual, subjective assessment of tube performance and indi-
cate that the biliary and duodenal secretions were efficiently
and entirely removed via the duodenal aspiration ports.
Specifically, Tc-99m mebrofenin and bile accumulated in a
small segment of the duodenum and were not visible in more
distal regions of the intestinal tract (Figure 3, Panels B, C, and
D). At times, Tc-99m mebrofenin was recovered as quickly as
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Figure 3. Animated gamma scintigraphic images of Tc-99m mebrofenin disposition (from 0 to 180 minutes). Clicking on each panel will
initiate animation: A, subject 1; B, subject 2; C, subject 3; D, subject 4. Hepatic uptake of Tc-99m mebrofenin was rapid, followed by
excretion into the canalicular space and accumulation in the gallbladder. Gallbladder contraction, facilitated by an IV infusion of cholecys-
tokinin-8 at 120 minutes, resulted in expulsion of bile containing Tc-99m mebrofenin from the gallbladder into the duodenum and subse-
quent aspiration via the oroenteric tube. (Animation available online only.)
Figure 4. Tc-99m mebrofenin blood concentration (red circles) and amount in bile (green triangles) versus time profiles, and the amount in
urine at 180 minutes (blue diamonds): A, subject 1; B, subject 2; C, subject 3; D, subject 4. Cholecystokinin-8 was administered at 120
minutes as a 30 minute IV infusion to facilitate contraction of the gallbladder.
The AAPS Journal 2004; 6 (4) Article 33 (http://www.aapsj.org).
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mulation of radioactivity in the duodenal region (Figure 3,
Panel D). In subject 1, the scintigraphic images also allowed
visualization of a small amount of Tc-99m mebrofenin that
leaked beyond the occlusive balloon after cholecystokinin-8
administration (Figure 3, Panel A). This observation corre-
sponded with a lower recovery of Tc-99m mebrofenin in sub-
ject 1 (Table 1). Static gamma camera images of subject 2 pre-
cholecystokinin-8 and post-cholecystokinin-8 (Figure 5)
clearly illustrate the efficiency of the oroenteric tube in
removing Tc-99m mebrofenin and bile from the duodenum.
At the conclusion of the sampling period (180 minutes post-
dose), residual radioactivity was evident in the gallbladder,
consistent with incomplete emptying of the gallbladder after
contraction.18,20 Using planar images obtained before and after
cholecystokinin-8 administration, the gallbladder ejection
fraction was determined (Table 1). With the exception of sub-
ject 3, remarkably large and consistent ejection fractions were
obtained. The extent of Tc-99m mebrofenin recovered in aspi-
rated bile exhibited high intersubject variability (35%-84% of
the administered dose); however, once corrected for the gall-
Table 1. Summary of Tc-99m Mebrofenin Dose, Recovery, Gallbladder Ejection Fraction, and Pharmacokinetic Parameters for Subjects
1, 2, 3, and 4*
Subject 1 Subject 2 Subject 3 Subject 4 Mean SD
Theoretical dose (µCi) 2188 2498 2500 2497 2421 155
Administered dose (µCi) † 2072 2282 2476 2277 202
Biliary recovery (% of dose‡) 65.5 84.3 35.2 83.5 67.1 23.0
Urinary recovery (% of dose‡) 0.7 0.5 0.8 0.5 0.6 0.2
Total recovery (% of dose‡) 66.2 84.8 36.0 84.0 67.8 22.8
Ejection fraction 0.82 0.86 0.03 0.86 0.64 0.4
Recovery of excreted dose (% of dose‡) 70.9 89.1 91.9 84.9 84.2 9.3
AUC0-∞ (nCi.min/mL) 1466 1613 1422 2305 1701 410
Cltotal (mL/min/kg) 16.4 16.2 19.9 16.7 17.3 1.7
AUC0-180 (nCi.min/mL) 1371 1462 1279 2054 1542 350
Clbiliary (mL/min/kg) 11.5 15.0 7.8 15.6 12.5 3.6
*AUC indicates area under the blood concentration-time curve, Cltotal = Dose/AUC0-∞, Clbiliary = (Mass in bile)0-180/AUC0-180
†Not determined, all calculations based on theoretical dose.
‡Administered dose, where available.
Figure 5. Static gamma camera images of subject 2 at 80 and 160 minutes after administration of Tc-99m mebrofenin. Tc-99 mebrofenin
accumulation in the intestine after 80 minutes was aspirated efficiently via the oroenteric tube as limited radioactivity was present in the
intestine by 160 minutes.
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bladder ejection fraction, the recovery of excreted Tc-99m
mebrofenin was consistently high (84.2% ± 9.3%, Table 1).
The blood concentration-time profiles, bile amount-time pro-
files, and the amount in urine at 180 minutes for subjects 1,
2, 3, and 4 are shown in Figure 4, Panels A, B, C, and D,
respectively. The blood profiles are similar in all subjects;
Cmax was followed by a rapid distributional phase and poly-
exponential decay. A terminal monoexponential decay phase
was not clearly evident after 3 hours of sampling. Table 1
summarizes the pharmacokinetic parameters obtained.
Systemic exposure and total body clearance were compara-
ble in all subjects, and biliary clearance ranged from 7.8 to
15.6 mL/min/kg (Table 1). The fraction of total clearance that
can be attributed to biliary excretion is numerically equiva-
lent to the biliary recovery (expressed as percentage of dose)
of Tc-99m mebrofenin reported in Table 1, averaging 78% in
subjects that responded to cholecystokinin-8 (subjects 1, 2,
and 4). The variability in biliary clearance was due primarily
to incomplete excretion of Tc-99m mebrofenin from the gall-
bladder during the collection period. The total amount of Tc-
99m mebrofenin recovered in urine 3 hours postdose was
very low (0.6% ± 0.2%).
DISCUSSION
This study used a customized oroenteric tube and tailored
clinical protocol to validate successfully an experimental pro-
cedure that allowed efficient collection of biliary secretions
from healthy human volunteers. In a previous pilot study, only
modest outcomes were obtained: gallbladder ejection frac-
tions after cholecystokinin-8 administration were abnormally
low, and the oroenteric tube used failed to completely collect
biliary secretions. It was hypothesized that the lack of
response to cholecystokinin-8 in the pilot study was a result
of the prolonged fasting period required by the protocol (the
intubation procedure took place the night before the study),
while the incomplete biliary recovery was due to the design of
the tube and the absence of an occlusive balloon. The clinical
protocol designed in the present study sought to maintain a
more physiologically normal gallbladder refilling state, there-
by maximizing the response to cholecystokinin-8. With the
exception of subject 3, subjects responded to the infusion of
cholecystokinin-8 in a manner typical for healthy volunteers,
with gallbladder ejection fractions greater than 0.8.17 To opti-
mize the filling status of the gallbladder during the study, sub-
jects received a high-fat evening meal and snack ~15 and 9
hours, respectively, prior to Tc-99m mebrofenin administra-
tion. This proved to be a successful method to ensure refilling
of the gallbladder the following day, as evidenced by the rapid
accumulation of Tc-99m mebrofenin in the gallbladder. These
results suggested that the gallbladder was not overfilled, a
state often associated with reduced bile flow, poor accumula-
tion of cholecystographic agents in the gallbladder, and in
some cases, significant spontaneous contraction of the gall-
bladder in interdigestive states.21
The oroenteric tube design used in the current study, and the
presence of an occlusive balloon, allowed for more complete
recovery of biliary secretions; a high percentage of the
administered dose was collected in bile in subjects 1, 2, and
4 (Table 1). Unfortunately, only the theoretical dose was
determined for subject 1, and a small amount of bile contain-
ing Tc-99m mebrofenin leaked past the occlusive balloon
(Figure 3), thus a lower than expected recovery of Tc-99m
mebrofenin was determined for this subject (Table 1).
The calculated ejection fraction theoretically represents the
fraction of gallbladder content that is expelled into the intestine
following infusion of cholecystokinin-8. Radioactivity
remaining in the gallbladder after contraction, therefore, repre-
sents the amount of Tc-99m mebrofenin irreversibly removed
from the systemic circulation that has not yet been excreted
into the intestine. By correcting the amount of Tc-99m mebro-
fenin collected in the bile during the infusion of cholecys-
tokinin-8 by the ejection fraction, and adding this value to the
biliary recovery from 0 to 120 minutes, the subsequent recov-
ery of Tc-99m mebrofenin represents the proportion of the
excreted dose that was collected by the oroenteric tube. The
recovery of excreted Tc-99m mebrofenin was high and exhib-
ited less variability, ranging from 70.9% to 91.9% of the
administered dose across all subjects. These results are consis-
tent with the extent of biliary excretion of Tc-99m mebrofenin
in humans (98% in 24 hours).22 The correction for incomplete
gallbladder ejection takes into account a poor or incomplete
response to cholecystokinin-8 (as observed for subject 3) and
demonstrates the efficiency of the oroenteric tube to collect
excreted Tc-99m mebrofenin from the duodenal region.
The Tc-99m mebrofenin blood concentration-time profiles
exhibited polyexponential decay (Figure 4), and a noncom-
partmental approach was employed to obtain primary phar-
macokinetic parameters (Table 1). The total systemic clear-
ance of Tc-99m mebrofenin (17.3 ± 1.7 mL/min/kg) approxi-
mated liver blood flow in humans (21 mL/min/kg)23 and was
in agreement with previously published animal and human
data.24 The calculated biliary clearance for subjects 1, 2, and
4 was 14.0 ± 2.2 mL/min/kg, consistent with the high biliary
excretion of Tc-99m mebrofenin, and represented over 66%
of the total body clearance observed in these subjects. The
poor ejection fraction observed in subject 3 resulted in a lower
recovery of Tc-99m mebrofenin, and subsequently, a lower
biliary clearance (7.8 mL/min/kg), representing only 35% of
the total body clearance for this subject. It is clear that if bile
could be collected for a longer time period, eventually all but
a fraction of the dose would be recovered in bile. However,
owing to practical constraints, it is not possible to keep the
balloon inflated for more than 3 to 4 hours. Therefore, quan-
titative assessment of the gallbladder ejection fraction is vital
The AAPS Journal 2004; 6 (4) Article 33 (http://www.aapsj.org).
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to the correct interpretation of the biliary clearance value
obtained in time-constrained studies such as those described
here. Similarly, although samples were collected only for 180
minutes, the cumulative amount of Tc-99m mebrofenin
excreted in the urine (0.6% ± 0.2%) was consistent with that
reported in the literature (2% over 24 hours).22
In conclusion, the oroenteric tube and clinical protocol devel-
oped in this study represent a useful method to investigate the
biliary excretion of the probe drug Tc-99m mebrofenin. The
custom-made oroenteric tube fitted with an occlusive balloon
allowed extremely efficient recovery of biliary secretions
from the duodenum. The approach described in this study
uses a combination of gamma scintigraphy and a carefully
designed clinical protocol to overcome variability in biliary
excretion and gallbladder responsiveness to cholecystokinin-
8 observed in previous studies.10,16 A similar experimental
design may be used to investigate the biliary excretion of a
variety of endogenous compounds and xenobiotics (includ-
ing investigational drugs) and to calculate biliary clearance,
a pharmacokinetic parameter that previously has been diffi-
cult to estimate or predict in healthy human subjects.
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